(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 January 2011 (20.01.2011)

PCT

(10) International Publication Number
WO 2011/008663 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *A61K 31/4427* (2006.01)
C07D 401/14 (2006.01) *A61P 3/10* (2006.01)

(21) International Application Number:
PCT/US2010/041645

(22) International Filing Date:
12 July 2010 (12.07.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09382114.8 15 July 2009 (15.07.2009) EP
61/245,445 24 September 2009 (24.09.2009) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventor; and
(71) Applicant : **BUENO MELENDO, Ana, Belen** [ES/ES]; Lilly S.a., Avenida de la Industria 30, 28108 Alcobendas, Madrid (ES).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BARRETT, David, Gene** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **FRANCISKOVICH, Jeffry, Bernard** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **LIU, Bin** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **TAKEUCHI, Kumiko** [US/US]; Eli Lilly And Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(74) Agents: **MYERS, James B.** et al.; ELI LILLY AND COMPANY, Patent Division, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: GPR119 AGONISTS



(I)

(57) **Abstract**: Abstract GPR119 agonist compounds of the formula: (I) and pharmaceutical compositions for the treatment of diabetes and obesity.

WO 2011/008663 A1